Cardiovascular Drugs Practice Questions

Q: What is the latest oral direct thrombin inhibitor?

Dabigatran. ### Explanation **Correct Answer: C. Dabigatran** **Mechanism and Rationale:** Dabigatran etexilate is a potent, competitive, and reversible **Direct Thrombin Inhibitor (DTI)**. Unlike heparin, which acts indirectly via antithrombin III, DTIs bind directly to the active site of both free and clot-bound thrombin (Factor IIa). It is administered as a prodrug and is currently the only orally available DTI approved for clinical use (e.g., for stroke prevention in atrial fibrillation and DVT prophylaxis). **Analysis of Incorrect Options:** * **A. Ximelagatran:** This was the first oral DTI developed. However, it was withdrawn from the market worldwide due to significant **hepatotoxicity** (elevation of liver enzymes). Dabigatran is the "latest" successful successor in this class. * **B. Idraparinux:** This is a long-acting synthetic polysaccharide that acts as an indirect **Factor Xa inhibitor**. It is administered subcutaneously, not orally. * **D. Fondaparinux:** This is a synthetic pentasaccharide that selectively inhibits **Factor Xa** by binding to antithrombin III. It is administered via subcutaneous injection and is not a thrombin inhibitor. **High-Yield Clinical Pearls for NEET-PG:** * **Reversal Agent:** The specific monoclonal antibody fragment used to reverse Dabigatran is **Idarucizumab** (Praxbind). * **Monitoring:** Unlike Warfarin, Dabigatran does not require routine INR monitoring. However, in emergencies, the **Diluted Thrombin Time (dTT)** or Ecarin Clotting Time (ECT) are the most sensitive tests. * **Excretion:** It is primarily eliminated by the **kidneys** (80%), so it must be used with caution or avoided in severe renal impairment. * **Comparison:** Remember the "Gatrans" (Dabigatran) are Thrombin (IIa) inhibitors, while the "Xabans" (Rivaroxaban, Apixaban) are Factor Xa inhibitors.

Q: When nitrates are combined with calcium channel blockers, what is the expected effect on hemodynamics?

Systemic blood pressure will decrease. ### Explanation The combination of **Nitrates** and **Calcium Channel Blockers (CCBs)** is a common pharmacological strategy in managing angina pectoris. Both drug classes act as potent vasodilators, leading to a synergistic reduction in systemic vascular resistance. **1. Why Option A is Correct:** Nitrates primarily cause venodilation (reducing preload), while CCBs (especially dihydropyridines like Amlodipine) primarily cause arterial dilation (reducing afterload). When used together, their combined effect on the vascular smooth muscle leads to a significant reduction in total peripheral resistance and venous return, resulting in a **decrease in systemic blood pressure**. **2. Why the Other Options are Incorrect:** * **B. Heart Rate:** While Nitrates can cause reflex tachycardia, combining them with **non-dihydropyridine CCBs** (like Verapamil or Diltiazem) actually helps **decrease or neutralize** the heart rate. Therefore, an increase is not the expected combined hemodynamic goal. * **C. Ejection Time:** Nitrates tend to decrease ejection time, but CCBs (especially those with negative inotropic effects) can increase it. The net effect is usually neutral or balanced, making this an unreliable expected outcome. * **D. End-Diastolic Volume (EDV):** Nitrates significantly **decrease EDV** by increasing venous capacitance (pooling blood in the veins). This is a beneficial effect as it reduces myocardial oxygen demand. **Clinical Pearls for NEET-PG:** * **The "Perfect Match":** Nitrates cause reflex tachycardia and increased contractility; Beta-blockers or non-DHP CCBs are added to block these compensatory mechanisms. * **Contraindication:** Never combine Nitrates with **Sildenafil** (PDE-5 inhibitors) as it can lead to life-threatening hypotension. * **Nitrate Tolerance:** Prevented by providing a "nitrate-free interval" (usually 8–12 hours at night).

Q: Which of the following antiplatelet drugs is a P2Y12 receptor blocker not affected by CYP2C19 polymorphism?

Prasugrel. **Explanation:** The correct answer is **Prasugrel**. **1. Why Prasugrel is correct:** Prasugrel is a third-generation thienopyridine P2Y12 receptor antagonist. Like clopidogrel, it is a prodrug; however, its metabolic activation is more efficient. It is rapidly hydrolyzed by esterases and then converted to its active metabolite by various CYP enzymes (primarily **CYP3A4 and CYP2B6**). Crucially, its activation is **not significantly dependent on CYP2C19**. Therefore, its antiplatelet efficacy is not affected by the genetic polymorphisms of CYP2C19 (poor metabolizers), leading to a more predictable and potent antiplatelet response compared to clopidogrel. **2. Why the other options are incorrect:** * **Clopidogrel:** This is a second-generation thienopyridine that relies heavily on a two-step hepatic activation process where **CYP2C19** plays a major role. Patients with a loss-of-function CYP2C19 allele are "poor metabolizers" and face a higher risk of cardiovascular events due to reduced active drug levels. * **Eptifibatide:** This is a **GP IIb/IIIa inhibitor**, not a P2Y12 blocker. It is administered intravenously and acts by preventing fibrinogen binding to platelets. * **Dipyridamole:** This drug acts primarily as a **phosphodiesterase (PDE) inhibitor**, increasing cAMP levels in platelets. It does not act on the P2Y12 receptor. **High-Yield Clinical Pearls for NEET-PG:** * **Ticagrelor** is another P2Y12 blocker not affected by CYP2C19 because it is **direct-acting** (not a prodrug) and binds reversibly. * **Prasugrel Contraindication:** It is strictly contraindicated in patients with a **prior history of stroke or TIA** due to a significantly increased risk of intracranial hemorrhage. * **Drug Interaction:** Avoid using **Omeprazole** (a CYP2C19 inhibitor) with Clopidogrel, as it reduces the antiplatelet effect. Pantoprazole is a safer alternative.

Q: Which of the following is a selective myosin activator?

Omecamtiv Mecarbil. **Explanation:** **Omecamtiv Mecarbil** is a novel **selective cardiac myosin activator** (cardiac inotrope) [1]. Unlike traditional inotropes, it does not increase intracellular calcium or cAMP. Instead, it binds directly to the catalytic domain of cardiac myosin, accelerating the rate-limiting step of the cross-bridge cycle (transition from the weak-binding to the strong-binding state). This increases the number of myosin heads bound to actin during systole, thereby increasing the **force of contraction** and **systolic ejection period** without increasing myocardial oxygen consumption or heart rate. **Analysis of Incorrect Options:** * **A. Istaroxime:** This is a dual-action investigational drug that inhibits Na+/K+ ATPase (like Digoxin) and activates the SERCA2a pump. It increases calcium sequestration but is not a direct myosin activator. * **C. Tolvaptan:** This is a selective **Vasopressin V2 receptor antagonist** (Aquaretic) used in the management of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD) [1]. * **D. Levosimendan:** This is a **Calcium Sensitizer** [1]. It binds to Troponin C, increasing the sensitivity of the contractile apparatus to existing calcium. It also acts as a K+ channel opener, causing vasodilation (Inodilator). **High-Yield Clinical Pearls for NEET-PG:** * **Omecamtiv Mecarbil** is specifically used in Heart Failure with Reduced Ejection Fraction (HFrEF) [1]. * **Key Advantage:** It improves cardiac function without the pro-arrhythmic risks associated with drugs that increase intracellular calcium (like Dobutamine or Milrinone). * **Mechanism Mnemonic:** "Omecamtiv **M**ecarbil **M**oves **M**yosin."

Q: A patient presents to the medicine emergency with severe CHF. A drug is chosen which is a short-term ionotropic agent with selective adrenergic agonistic activity but lacking dopaminergic agonistic activity. What can this drug be?

Dobutamine. **Explanation:** The patient is presenting with severe Congestive Heart Failure (CHF), requiring an inotropic agent to improve cardiac output. **Why Dobutamine is correct:** Dobutamine is a synthetic catecholamine that acts as a **selective $\beta_1$-adrenergic agonist**. It increases myocardial contractility (positive inotropy) with a relatively lesser effect on heart rate (chronotropy). Crucially, unlike dopamine, it has **no action on dopaminergic ($D_1, D_2$) receptors**. It is the drug of choice for short-term management of cardiac decompensation post-surgery or in CHF/cardiogenic shock. **Why other options are incorrect:** * **Dopamine:** While it is an inotrope, it acts on **dopaminergic receptors** (causing renal vasodilation at low doses) as well as $\beta_1$ and $\alpha_1$ receptors. The question specifically excludes dopaminergic activity. * **Amrinone (Inamrinone):** This is a **Phosphodiesterase-3 (PDE3) inhibitor**, not an adrenergic agonist. It increases cAMP levels to exert inotropic effects but works via a different mechanism than the one described. * **Salmeterol:** This is a long-acting **$\beta_2$-selective agonist** used primarily as a bronchodilator in asthma/COPD; it is not used as an inotropic agent in acute CHF. **High-Yield Clinical Pearls for NEET-PG:** * **Dobutamine** is often preferred over Dopamine in cardiogenic shock because it reduces afterload (slight $\beta_2$ effect) and has a lower tendency to cause tachycardia. * **Isoprenaline** is a non-selective $\beta$-agonist ($\beta_1 = \beta_2$), whereas Dobutamine is $\beta_1$ selective. * **Tolerance:** Tachyphylaxis (decreased response) can occur with Dobutamine if used continuously for more than 72 hours due to receptor down-regulation.

Q: A 70-year-old female presents to the emergency department with chest pain. Her ECG shows ventricular tachycardia with ST-segment elevation, and troponin levels are elevated, leading to a diagnosis of STEMI. What is the initial treatment for the arrhythmia?

Lidocaine. ### Explanation **Correct Option: A. Lidocaine** In the setting of an acute myocardial infarction (STEMI), the myocardium becomes ischemic and acidic. **Lidocaine**, a Class IB antiarrhythmic, is the drug of choice for ventricular arrhythmias associated with acute MI. * **Mechanism:** It selectively binds to sodium channels in the **inactivated state**. Ischemic tissue stays depolarized longer, keeping channels in the inactivated state, which allows Lidocaine to preferentially block sodium entry in damaged cells while sparing healthy tissue. * **Key Concept:** It has little effect on normal conduction but effectively suppresses automaticity in ischemic ventricular fibers. **Why other options are incorrect:** * **B. Adenosine:** This is the drug of choice for Paroxysmal Supraventricular Tachycardia (PSVT). It acts on the AV node and is ineffective for ventricular arrhythmias. * **C. Quinidine:** A Class IA antiarrhythmic. It is contraindicated in MI because it can prolong the QT interval, potentially leading to Torsades de Pointes, and has significant anticholinergic side effects. * **D. Verapamil:** A Calcium Channel Blocker (Class IV). It is used for rate control in atrial arrhythmias (like AFib) but is contraindicated in ventricular tachycardia as it can precipitate severe hypotension and cardiovascular collapse. **NEET-PG High-Yield Pearls:** * **Class IB (Lidocaine, Mexiletine):** "IB is Best post-MI." They have the shortest recovery time from channel binding. * **Route:** Lidocaine must be given **IV** due to extensive first-pass metabolism. * **Toxicity:** Overdose primarily affects the CNS (seizures, tremors, slurred speech). * **Current ACLS Guidelines:** While Amiodarone is now often used first-line for stable VT, Lidocaine remains the classic pharmacological answer for **ischemia-induced** ventricular arrhythmias in exam scenarios.

Question 1

What is the latest oral direct thrombin inhibitor?

Accepted Answer

Dabigatran

Answer

Ximelagatran

Answer

Indraparinux

Answer

Fondaparinux

Question 2

Which of the following is most useful for reversing ergot-induced vasospasm?

Accepted Answer

Nitroprusside

Answer

Ergotamine

Answer

Methysergide

Answer

Phenoxybenzamine

Question 3

What is the mechanism of action of digitalis in atrial fibrillation?

Accepted Answer

Increase in refractoriness of the AV nodal tissue

Answer

Causing bradycardia

Answer

Na+ K+ ATPase inhibition

Answer

Causing bradycardia

Question 4

When nitrates are combined with calcium channel blockers, what is the expected effect on hemodynamics?

Accepted Answer

Systemic blood pressure will decrease

Answer

Heart rate will increase

Answer

Ejection time will decrease

Answer

End-diastolic volume will increase

Question 5

Which of the following antiplatelet drugs is a P2Y12 receptor blocker not affected by CYP2C19 polymorphism?

Accepted Answer

Prasugrel

Answer

Clopidogrel

Answer

Eptifibatide

Answer

Dipyridamole

Question 6

Which drug is most likely to cause maximum tachycardia?

Accepted Answer

Nifedipine

Answer

Verapamil

Answer

Propranolol

Answer

Amlodipine

Question 7

Which of the following is a selective myosin activator?

Accepted Answer

Omecamtiv Mecarbil

Answer

Istaroxime

Answer

Tolvaptan

Answer

Levosimendan

Question 8

Nicotinic acid acts by which of the following mechanisms?

Accepted Answer

Inhibiting the release of free fatty acids from adipose tissue

Answer

Inhibiting HMG-CoA synthatase

Answer

Inhibiting HMG CoA reductase

Answer

Decreasing absorption of cholesterol

Question 9

A patient presents to the medicine emergency with severe CHF. A drug is chosen which is a short-term ionotropic agent with selective adrenergic agonistic activity but lacking dopaminergic agonistic activity. What can this drug be?

Accepted Answer

Dobutamine

Answer

Dopamine

Answer

Amrinone

Answer

Salmeterol

Question 10

A 70-year-old female presents to the emergency department with chest pain. Her ECG shows ventricular tachycardia with ST-segment elevation, and troponin levels are elevated, leading to a diagnosis of STEMI. What is the initial treatment for the arrhythmia?

Accepted Answer

Lidocaine

Answer

Adenosine

Answer

Quinidine

Answer

Verapamil

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?